Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether recombinant human hepatocyte growth factor
is safe and effective in the treatment of fulminant and late-onset hepatic failure.